22 June 2020 : Clinical Research
Association of Serum Thyroid Hormones with the Risk and Severity of Chronic Kidney Disease Among 3563 Chinese Adults
Jialin Li1CE, Xi’ai Wu2BD, Minjing Luo1BF, Meihua Yan3BD, Qian Wang1D, Ping Li3AG, Wenquan Niu3CE*DOI: 10.12659/MSM.922910
Med Sci Monit 2020; 26:e922910
Table 1 Baseline characteristics of study participants in this retrospective study.
| Characteristics | Controls | Patients with chronic kidney disease (CKD) | |||
|---|---|---|---|---|---|
| Stage 1–2 | Stage 3 | Stage 4 | Stage 5 | ||
| Sample size | 289 | 471 | 544 | 1214 | 1045 |
| Age (years) | 62 (53–69) | 68 (56–75)** | 73 (65–77)** | 70 (60–76)** | 59 (47–68)** |
| Male (n, %) | 236, 81.7 | 325, 69** | 428, 78.7 | 819, 67.5** | 588, 56.3** |
| Hypertension (n, %) | 175, 60.6 | 308, 65.4 | 354, 65.1 | 875, 72.1** | 819, 78.36** |
| Diabetes (n, %) | 111, 38.4 | 179, 38.0 | 211, 38.8 | 544, 44.8* | 356, 34.1 |
| TG (mmol/L) | 1.38 (1.00–1.90) | 1.32 (0.94–2.03) | 1.36 (0.95–1.95) | 1.51 (1.05–2.20)** | 1.54 (1.08–2.19)** |
| TC (mmol/L) | 4.30 (3.52–4.96) | 4.02 (3.08–4.80)** | 3.720 (2.94–4.57)** | 3.950 (3.16–4.94)** | 4.18 (3.45–5.00) |
| LDL-C (mmol/L) | 2.56 (1.98–3.08) | 2.29 (1.59–2.92)** | 2.11 (1.49–2.74)** | 2.29 (1.64–3.06)** | 2.42 (1.88–3.09) |
| HDL-C (mmol/L) | 1.01 (0.84–1.21) | 0.97 (0.72–1.22)* | 0.86 (0.61–1.08)** | 0.91 (0.68–1.17)** | 1.00 (0.78–1.24) |
| HbA1c (%) | 6.10 (5.50–7.10) | 6.20 (5.50–7.20) | 6.40 (5.80–7.30)* | 6.40 (5.70–7.30)* | 5.90 (5.30–6.70)** |
| UA (μmol/L) | 333 (285–387) | 314 (218–444) | 384 (274–500)** | 442 (345–548)** | 404 (316–502)** |
| Scr (μmol/L) | 75 (66.10–85) | 77.40 (62.90–92.65) | 143.8 (121–169)** | 236 (203.3–283)** | 635.9 (463.6–859)** |
| ACR (mg/g) | 5.70 (4.20–9.10) | 64.80 (44.10–80.30)** | 21.35 (6.60–62.10)** | 126.9 (36.10–317.30)** | 220.6 (126.30–429.50)** |
| BUN (mmol/L) | 5.44 (4.46–6.75) | 9.07 (5.72–14.88)** | 11.65 (8.86–15.89)** | 15.24 (11.79–20.13)** | 21.24 (16.10–27.36)** |
| T3 (ng/mL) | 0.97 (0.86–1.08) | 0.76 (0.61–0.95)** | 0.63 (0.47–0.81)** | 0.70 (0.52–0.87)** | 0.74 (0.57–0.93)** |
| T4 (μg/dL) | 7.22 (6.21–8.30) | 6.76 (5.58–8.40)* | 6.20 (4.80–7.70)** | 6.51 (5.33–7.82)** | 6.30 (5.17–7.61)** |
| FT3 (pg/mL) | 2.88 (2.64–3.09) | 2.23 (1.79–2.69)** | 2.00 (1.50–2.43)** | 2.07 (1.60–2.47)** | 2.15 (1.69–2.58)** |
| FT4 (ng/dL) | 1.19 (1.08–1.34) | 1.15 (1.00–1.32)** | 1.15 (0.96–1.37)* | 1.15 (0.98–1.31)** | 1.10 (0.93–1.27)** |
| TSH (μIU/mL) | 1.79 (1.20–2.71) | 1.46 (0.72–2.37)* | 1.53 (0.65–3.23) | 2.17 (1.14–4.10)* | 2.23 (1.28–3.75)** |
| P values are calculated by nonparametric Wilcoxon rank sum tests for continuous variables expressed as median (interquartile range) and χ tests for categorical variables expressed as count and percent. TG – triglycerides; TC – total cholesterol; LDL-C – low-density lipoprotein cholesterol; HDL-C – high-density lipoprotein cholesterol; HbA1c – hemoglobin A1c; UA – uric acid; Scr – serum creatinine; ACR – albumin-to-creatinine ratio; BUN – blood urea nitrogen; T3 – total triiodothyronine; T4 – total thyroxine; FT3 – free triiodothyronine; FT4 – free thyroxine; TSH – thyroid-stimulating hormone. * P ** P | |||||